FDA 执法报告 D-0111-2027:Brandywine 茶碱缓释片 200 mg 因第三方实验室稳定性试验中断被列为 II 类召回
FDA drug enforcement D-0111-2027: Brandywine Pharmaceuticals, LLC — CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
openFDA 执法报告 D-0111-2027 显示,Brandywine Pharmaceuticals 的茶碱缓释片 200 mg(批号 405620,有效期 2028 年 3 月 31 日)因第三方实验室稳定性试验中断的 CGMP 偏差,被列为 II 类自愿召回。
记录显示该企业自愿召回的分类结果为 II 类,原因指向第三方实验室稳定性试验中断,可据此核对批次与分销范围。
FDA 药品召回执法报告 — D-0111-2027
报告发布日期:2026-11-04。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所对应的含义。
完整官方产品记录(包括 openFDA 统一标识符):
{
"address_1": "600 W Strasburg Rd",
"address_2": "",
"center_classification_date": "20261029",
"city": "West Chester",
"classification": "Class II",
"code_info": "Lot: 405620, Expiry: 03/31/2028.",
"country": "United States",
"distribution_pattern": "Nationwide within U.S",
"event_id": "100038",
"initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",
"more_code_info": "",
"openfda": {},
"postal_code": "19382-1955",
"product_description": "Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.",
"product_quantity": "1,332 100-count bottles",
"product_type": "Drugs",
"reason_for_recall": "CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory",
"recall_initiation_date": "20261006",
"recall_number": "D-0111-2027",
"recalling_firm": "Brandywine Pharmaceuticals, LLC",
"report_date": "20261104",
"state": "PA",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov